These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1799913)

  • 1. Transfer of patients with diabetes from semisynthetic human insulin to human insulin prepared by recombinant DNA technology using baker's yeast: a double-blind, randomized study.
    Davidson JA; Ramirez LC; Raskin P; Selam JL
    Clin Ther; 1991; 13(5):557-68. PubMed ID: 1799913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of human insulin derived from baker's yeast by recombinant DNA technology.
    Raskin P; Clements RS
    Clin Ther; 1991; 13(5):569-78. PubMed ID: 1799914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin antibodies in non-insulin-dependent diabetes mellitus: effect of treatment with semisynthetic human insulin.
    Lauritano AA; Clements RS; Bell D
    Clin Ther; 1989; 11(2):268-77. PubMed ID: 2660998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens.
    Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
    Diabetes Care; 1989 Feb; 12(2):115-9. PubMed ID: 2649324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fixed-ratio versus variable-ratio regular and NPH semisynthetic human insulin in insulin-requiring diabetic patients.
    Khachadurian AK; Davidson JA; Braunstein S; Redmond G; Greenfield M; Lauritano AA; Haycock P
    Clin Ther; 1989; 11(4):485-94. PubMed ID: 2673516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different daily blood glucose control and free insulin levels during treatment with mixtures of soluble and lente or soluble and NPH semisynthetic human insulins.
    Cucinotta D; Di Benedetto A; Gigante A; Di Cesare E; Musolino C; Squadrito G
    Diabete Metab; 1989; 15(4):182-7. PubMed ID: 2680669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM.
    Wolfsdorf JI; Laffel LM; Pasquarello C; Vernon A; Herskowitz RD
    Diabetes Care; 1991 Nov; 14(11):1100-6. PubMed ID: 1797498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E; Lang H; Roberts A
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
    Herz M; Sun B; Milicevic Z; Erickson P; Fövènyi J; Grzywa M; Pelikanova T
    Clin Ther; 2002 Jan; 24(1):73-86. PubMed ID: 11833837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a premixed insulin regimen (Novolin 70/30) to replace self-mixed insulin regimens.
    Aronoff S; Goldberg R; Kumar D; Lichtenstein E; Schwartz S; Sosenko J
    Clin Ther; 1994; 16(1):41-9. PubMed ID: 8205600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
    Rosenstock J; Schwartz SL; Clark CM; Park GD; Donley DW; Edwards MB
    Diabetes Care; 2001 Apr; 24(4):631-6. PubMed ID: 11315821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
    Ratner RE; Hirsch IB; Neifing JL; Garg SK; Mecca TE; Wilson CA
    Diabetes Care; 2000 May; 23(5):639-43. PubMed ID: 10834423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
    Garg SK; Paul JM; Karsten JI; Menditto L; Gottlieb PA
    Diabetes Technol Ther; 2004 Oct; 6(5):589-95. PubMed ID: 15628812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.
    Aronson R; Reznik Y; Conget I; Castañeda JA; Runzis S; Lee SW; Cohen O;
    Diabetes Obes Metab; 2016 May; 18(5):500-7. PubMed ID: 26854123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of human ultralente- and lente-based twice-daily injection regimens.
    Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
    Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the safety and effectiveness of human and bovine long-acting insulins.
    Selam JL; Turner D; Woertz L; Eichner HL; Lauritano A; Charles MA
    Diabetes Res; 1989 Nov; 12(3):131-4. PubMed ID: 2635094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.